Long-Term Safety and Efficacy of Prolonged Dual Antiplatelet Therapy according to Baseline Anemia after Percutaneous Coronary Intervention

Figures

• 

  Fig. 1. Study population. (A) Study population selection process. (B) DAPT continuation rate between patients with and without anemia. DAPT, dual antiplatelet therapy; DES, drug-eluting stent.

• 

  Fig. 2. Kaplan-Meier survival curves according to anemia and the duration of dual antiplatelet therapy. *p-value between ≤12-m and >12-m DAPT in patients without anemia, †p-value between ≤12-m and >12-m DAPT in patients with anemia. MACCE, major adverse cardiovascular and cerebrovascular event; DAPT, dual antiplatelet therapy; DES, drug-eluting stent.

• 

  Fig. 3. Correlation between the incidence of adverse clinical outcomes and baseline hemoglobin. (A) There was a significant linear negative correlation between the incidence of MACCEs and baseline hemoglobin. (B) The incidence of major bleeding and baseline hemoglobin was also negatively correlated. MACCE, major adverse cardiovascular and cerebrovascular event; HR, hazard ratio.